Form 4 for ALDX Aldeyra Therapeutics, Inc.

Accepted 2022-04-01 00:00:00 ET · period of report 2022-03-30 · accession 0000899243-22-013176 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
D	2022-04-01	2022-03-30	ALDX	Brady Todd C	Pres, CEO, Dir	A - Grant	$0.00	+250.0K	1.20M	+26%	$0
DM	2022-04-01	2022-03-30	ALDX	Brady Todd C	Pres, CEO, Dir	A - Grant	$0.00	+457.8K	207.8K	New	$0

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2022-03-30	A	A	250,000	$0.00	1,198,835	D	—	—	(F1) Represents shares of common stock underlying a time-based restricted stock unit award (RSU). The RSU vests ratably in equal annual installments over a four-year period beginning on January 1, 2022, provided that the Reporting Person has provided continuous service to the Issuer through the applicable vesting date.
2	Derivative	Employee Stock Option (Right to Buy)	2022-03-30	A	A	250,000	$0.00	250,000	D	$4.52 · — to 2032-03-29	250,000 Common Stock	(F2) The shares subject to this option shall vest in equal monthly installments over the next 48 months of continuous service to the Issuer after January 1, 2022.
3	Derivative	Bonus Units	2022-03-30	A	A	207,758	$0.00	207,758	D	$4.52 · — to —	207,758 Common Stock	(F3) The bonus units vest in four (4) annual installments from the date of grant and entitle the Reporting Person to receive a cash payment, on the earlier of (i) four (4) years from the date of grant or (ii) a Change of Control of the Issuer (as defined in the grant documents), equal in value to the amount by which the then value of the Issuer's common stock exceeds the base value of $4.52.